Up-Regulation of Cyclooxygenase-2 Expression Is Involved inR(+)-Methanandamide-Induced Apoptotic Death of Human Neuroglioma Cells
- 10 September 2004
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET)
- Vol. 66 (6), 1643-1651
- https://doi.org/10.1124/mol.104.002618
Abstract
Cannabinoids have been implicated in the reduction of glioma growth. The present study investigated a possible relationship between the recently shown induction of cyclooxygenase (COX)-2 expression by the endocannabinoid analog R(+)methanandamide [R(+)-MA] and its effect on the viability of H4 human neuroglioma cells. Incubation with R(+)-MA for up to 72 h decreased the cellular viability and enhanced accumulation of cytoplasmic DNA fragments in a time-dependent manner. Suppression of R(+)-MA-induced prostaglandin (PG) E2 synthesis with the selective COX-2 inhibitor celecoxib (0.01-1 μM) or inhibition of COX-2 expression by COX-2-silencing small-interfering RNA was accompanied by inhibition of R(+)-MA-mediated DNA fragmentation and cell death. In contrast, the selective COX-1 inhibitor SC-560 was inactive in this respect. Cells were also protected from apoptotic cell death by other COX-2 inhibitors (NS-398 {[N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide]} and diclofenac) and by the ceramide synthase inhibitor fumonisin B1, which interferes with COX-2 expression by R(+)-MA. Moreover, the proapoptotic action of R(+)-MA was mimicked by the major COX-2 product PGE2. Apoptosis and cell death by R(+)-MA were not affected by antagonists of cannabinoid receptors (CB1, CB2) and vanilloid receptor 1. In further experiments, celecoxib was demonstrated to suppress apoptotic cell death elicited by anandamide, which is structurally similar to R(+)-MA. As a whole, this study defines COX-2 as a hitherto unknown target by which a cannabinoid induces apoptotic death of glioma cells. Furthermore, our data show that pharmacological concentrations of celecoxib may interfere with the proapoptotic action of R(+)-MA and anandamide, suggesting that cotreatment with COX-2 inhibitors could diminish glioma regression induced by these compounds.Keywords
This publication has 34 references indexed in Scilit:
- A new strategy to block tumor growth by inhibiting endocannabinoid inactivationThe FASEB Journal, 2004
- Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interferenceOncogene, 2003
- Analysis of gene function in somatic mammalian cells using small interfering RNAsMethods, 2002
- Cyclooxygenase-2—10 Years LaterJournal of Pharmacology and Experimental Therapeutics, 2002
- R(+)-Methanandamide Induces Cyclooxygenase-2 Expression in Human Neuroglioma Cells via a Non-cannabinoid Receptor-Mediated MechanismBiochemical and Biophysical Research Communications, 2001
- Cyclooxygenase-2 Expression in Lipopolysaccharide-Stimulated Human Monocytes Is Modulated by Cyclic AMP, Prostaglandin E2, and Nonsteroidal Anti-inflammatory DrugsBiochemical and Biophysical Research Communications, 2000
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Microtubule-interfering Agents Stimulate the Transcription of Cyclooxygenase-2Published by Elsevier BV ,2000
- HIV-1 gp120-Induced Apoptosis in the Rat Neocortex Involves Enhanced Expression of Cyclo-oxygenase Type 2 (COX-2)Biochemical and Biophysical Research Communications, 1998
- Antagonism of marihuana effects by indomethacin in humansLife Sciences, 1991